Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467880 | 0.79 | NOS1 (0.42) | NOS1NOS2KDM4EKMT2AADORA2A | |
| SCHEMBL5731388 | 0.74 | KDM4E (0.44) | KDM4EKMT2AALDH1A1CYP1A2MAPT | |
| SCHEMBL20361158 | 0.69 | KDM4E (0.52) | NOS1NOS2KDM4EADORA2AADORA1 | |
| SCHEMBL19267552 | 0.68 | NOS1 (0.45) | NOS1NOS2KDM4EKMT2AADORA2A | |
| SCHEMBL6111556 | 0.68 | XDH (0.31) | — | |
| SCHEMBL1309845 | 0.66 | ERCC5 (0.54) | KDM4EKMT2AGAAALDH1A1HSD17B10 | |
| SCHEMBL10276899 | 0.66 | PIM1 (0.41) | MAPT | |
| SCHEMBL29453046 | 0.66 | PIM1 (0.41) | MAPT | |
| SCHEMBL29453041 | 0.66 | PIM1 (0.41) | MAPT | |
| SCHEMBL1320706 | 0.65 | KDM4E (0.46) | KDM4EKMT2AADORA2AADORA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190040079-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190040079-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2019-02-07 | — | — | US | disclosed |
| US-9938290-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938290-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938290-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20180009826-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2018-01-11 | — | — | US | disclosed |
| US-20180009826-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2018-01-11 | — | — | US | disclosed |
| US-9580442-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9580442-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-9580442-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160108057-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2016-04-21 | — | — | US | disclosed |
| US-20160108057-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2016-04-21 | — | — | US | disclosed |
| US-20160108057-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2016-04-21 | — | — | US | disclosed |
| US-9200007-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| US-9200007-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| US-9200007-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2015-12-01 | — | — | US | disclosed |
| EP-2467387-B1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS. | KARUS THERAPEUTICS LTD (GB) | 2015-01-07 | — | — | EP | disclosed |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2012-07-12 | — | — | US | disclosed |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2012-07-12 | — | — | US | disclosed |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009826-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3C2A | NOS1 2997/4885NOS2 3228/4885KDM4E 2632/4885 |
| US-20120178737-A1 | Tricyclic Heterocyclic Compounds as Phosphoinositide 3-Kinase Inhibitors | PIK3CA, PIK3CD, PIK3C2A | NOS1 3080/4885NOS2 3303/4885KDM4E 2630/4885 |
| US-20190040079-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3R2 | NOS1 3083/4885NOS2 3319/4885KDM4E 2632/4885 |
| US-20160108057-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3R2, PIK3R1, PIK3CA | NOS1 3545/4885NOS2 3447/4885KDM4E 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.